Award Data

PROJECT SUMMARY Actively involving informal caregivers in direct patient care at the bedside in the intensive care unit (ICU) has the potential to improve patient, informal caregiver, and health care system outcomes. Practice guidelines call for the liberal inclusion of informal caregivers as active partners in ICU care, but there is a critical, unmet need to develop tools that effectively operati ...

ABSTRACT This Phase STTR Phase II proposal aims to engineer and scale-up a synthetic metabolic pathway in a microbial host to produce UDCA and related compounds. Additionally, the UDCA produced from the engineered synthetic metabolic pathway will be used to synthesize derivatives for testing in our Alzheimer’s Disease cell and animal models. The proposed work has high intellectual merit for the ...

Project Summary The proposed project will develop a breakthrough endovascular sensor technology to allow for real-time quantification of the mitral coaptation force (MCF) of the mitral valve during both open and percutaneous mitral valve repair (MVR). Mitral regurgitation (MR) is the most common heart valve disorder in the U.S. population, with over 2 million individuals affected. Current methods ...

Project Summary MarPam Pharma aims to develop a one-time treatment for achieving durable remission of human immunodeficiency virus (HIV), after which patients will no longer need to take antiretroviral therapy. Our treatment is an autologous HIV-specific chimeric antigen receptor (CAR) immune cell therapy that employs the CXCR5 chemokine receptor as a homing device to direct either anti-HIV T cell ...

PROJECT SUMMARY Data is a critical and highly valuable commodity, driving meaningful change in our society, especially when it pertains to patient care and biomedical research. Currently, institutions pay inordinate sums to increase, regain, and complement their data panels. As an extra burden, data legislation and privacy protection regulations introduce barriers to forming effective partnerships ...

ABSTRACT SaCas9 is a major gene editing nuclease that is preferred for in vivo applications thanks to its relatively smaller size compared to that of spCas9. One limiting factor for the use of saCas9 is its strict PAM requirement of NNGRRT. In addition, there are limited efforts to reduce saCas9’s off-target editing rates. In Aim 1, we propose a computational approach to relax saCas9’s PAM req ...

Tarn Biosciences, Inc. is a start-up pharmaceutical company headquartered in East Lansing, Michigan. The company is developing new therapies for tuberculosis (TB). The goal of this STTR is to develop the MmpL3 inhibitor, HC2099, as a new treatment for drug susceptible and multidrug-resistant TB (MDR-TB). In 2019, 10 million people worldwide fell ill to TB with ~ 1.4 million lives lost. Standard-of ...

PROJECT SUMMARY/ABSTRACT The long-term goal of this proposal is to improve the care of patients suffering from Large Vessel Occlusion Acute Ischemic stroke. Currently, mechanical thrombectomy techniques can achieve revascularization in over 70% of cases, and physicians are rapidly adoption aspiration thrombectomy over stent-trievers. Aspiration maintains equivalent angiographic and clinical outcom ...

PROJECT SUMMARY Genomics has become an essential element of biomedical science, playing multiple roles in rapidly addressing the COVID-19 pandemic, understanding medical complications to develop more effective preventative care and treatments, and modeling diseases in laboratory specimens for study. Despite the increasing relevance of genomics to people's everyday lives, genomics literacy in the U ...

PROJECT SUMMARY/ABSTRACTUsher syndrome type 3A (USH3A), an autosomal recessive disorder, is characterized by progressive loss of hearing and vision due to a clarin-1 (CLRN1) gene mutation. A person with type 3 Usher syndrome will usually require cochlea implants by mid- to late adulthood and classified as being legally blind. The management of the chronic, progressive, severe vision loss (retiniti ...